• Users Online: 339
  • Print this page
  • Email this page
 
CASE REPORT
Ahead of Print

Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination


1 Department of Ophthalmology, Tsukazaki Hospital, Himeji, Hyogo, Japan
2 Department of Ophthalmology, Tsukazaki Hospital, Himeji, Hyogo; Department of Technology and Design Thinking for Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Hiroshima; Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Tokushima, Japan
3 Kurusu Eye Clinic, Himeji, Hyogo, Japan
4 Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Tokushima, Japan

Correspondence Address:
Daisuke Nagasato,
Department of Ophthalmology, Tsukazaki Hospital, 68-1 Waku, Aboshi-ku, Himeji, Hyogo 671-1227
Japan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tjo.tjo_24_22

In this article, we report two patients who experienced the first onset of branch retinal vein occlusion (BRVO) 3 days after the administration of the BNT162b2 (Pfizer–BioNTech) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Case 1: A 50-year-old woman without any history of retinal disease developed vision loss in her right eye 3 days after receiving the first dose of the SARS-CoV-2 mRNA vaccine. Case 2: A 56-year-old woman without any history of retinal disease developed vision loss in her right eye 3 days after receiving the first dose of the SARS-CoV-2 mRNA vaccine. Case 1: Temporal superior BRVO and secondary macular edema (ME) were observed in the patient's right eye. Her best-corrected visual acuity (BCVA) was 20/25. Case 2: Temporal inferior BRVO and secondary ME were observed in the patient's right eye. Her BCVA was 13/20. Case 1: Three doses of intravitreal ranibizumab (IVR) were administered. Case 2: Three doses of IVR were administered. Case 1: ME resolved and BCVA improved to 20/20. Case 2: ME resolved and BCVA improved to 20/20. Both the cases showed a possible association between the SARS-CoV-2 vaccination and the first onset of BRVO.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Tanaka H
    -  Nagasato D
    -  Nakakura S
    -  Nagasawa T
    -  Wakuda H
    -  Kurusu A
    -  Mitamura Y
    -  Tabuchi H
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed713    
    PDF Downloaded5    

Recommend this journal